An HIV Vaccine: The World's best long-term hope for ending AIDS.

Who We Are

We are the world’s largest publicly-funded international collaboration focused on the development of vaccines to prevent HIV/AIDS. Learn more >

What We Do

Our sites conduct all phases of clinical trials - from evaluating experimental vaccines for safety and immunogenicity to testing vaccine efficacy. Learn more >

Get Involved

Worldwide, thousands of people have participated in HIV vaccine trials.  Volunteers are the heroes of vaccine development. Learn more >

Michele Andrasik, PhD

Study Participants Feel Good When Helping Others, HVTN Analysis Shows

A NIAID-funded HIV Vaccine Trials Network (HVTN) cross-protocol analysis designed to assess the self-reported beneficial and negative social impacts (NSI) experienced by study participants was published earlier this year in the Journal of Acquired Immune Deficiency Syndromes (JAIDS). The study enrolled 8347 people across 48 completed preventive HIV vaccine trials, which were conducted between December 2000 and September 2017.

Read Story >

Design by Cody Shipman

Volume 20, Issue 2: The Latest Issue of Community Compass

The Community Compass aims to keep the HVTN community informed about the Network’s research, sites' activities, and advances in the field of HIV Prevention and Vaccination. Read the latest issue >

Aziel Gangerdine

Reflections On Communicating Hope From The Ground Up in commemoration of World AIDS Day

Earlier this year I lost a dear friend and confidant to Covid-19. Gita Ramjee was a globally renowned HIV prevention researcher who drew inspiration from the communities she worked with in South Africa, the world’s epicenter of the HIV and AIDS epidemic. Gita advocated for the need to develop more proven HIV prevention strategies to help women protect themselves from HIV. 

Human Immunodeficiency Virus, better known as HIV, was first identified as the cause of Acquired, Immunodeficiency Syndrome (AIDS) in 1984, and the National Institute of Allergy and Infectious Diseases (NIAID) opened the first HIV vaccine clinical trial in 1987. The NIAID-funded HIV Vaccine Trials Network (HVTN) is the world's largest publicly-funded collaboration to develop a vaccine for HIV/AIDS, and since its inception in 1999 has conducted more than 80 clinical trials in more than a dozen countries, involving more than 22,000 study participants.

Read Story >

Scholar Awards

We support the next generation of HIV researchers with structured mentoring, projects, training, and networking opportunities. Learn more >

Getting the Right Test for HIV

Getting the right test will prevent an incorrect diagnosis of HIV.  Your study site or VISP Testing Service can provide the right test.  Visit our frequently asked questions for more information.

Formation of the COVID-19 Prevention Network (CoVPN) and official website launch

CoVPN Logo
  • The COVID-19 Prevention Network (CoVPN) was formed by the National Institute of Allergy and Infectious Diseases (NIAID) at the US National Institutes of Health to respond to the global pandemic. Using the infectious disease expertise of their existing research networks and global partners, NIAID has directed the networks to address the pressing need for vaccines and monoclonal antibodies (mAbs) against SARS-CoV-2. The HVTN is one of four NIAID-funded networks that constitute the CoVPN.
  • Access the official website:  
  • Read more about the CoVPN’s observational studies currently underway:



HIV Vaccine Trials Network

Fred Hutchinson Cancer Research Center